Viatris Acts Pretty Volatile Lately: Time To Reconsider?

Viatris rose by 0.07% in the latest trading session. During the past month, shares of the generic drugmaker have gained 2.9%. The Medical sector has also gained 4.38%. On November 8, 2021, Viatris’ (VTRS) shares are expected to report earnings of $0.86 per share. The company’s sales are expected to grow at a robust rate of 46.98%. For the full year, the consensus earnings per share estimate is $3.61, while the revenue projection is $17.76 billion. Any changes in analyst forecasts for VTRS should be noted by investors.

Based on Zack’s research, these revisions are related to near-team stock moves. The Zacks Rank was created to capitalize on these changes. The proven model includes stocks that have the potential to beat the market, and the Zacks Rank system shows that those stocks are likely to perform well. VTRS’ Forward P/E ratio is 3.83. This is a discount compared to its industry average Forward P/E of 31.19. This industry is part of the Medical Services sector. The Zacks Industry Rank measures the strength of the industry groups within the S&P 500. The top 50% of rated stocks outperform the bottom half.